{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-036830","form_type":"8-K","ticker":"ACHV","cik":"0000949858","company_name":"ACHIEVE LIFE SCIENCES, INC.","filed_at":"2025-03-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.915585+00:00","generated_at":"2026-05-25T00:36:52.412556+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Achieve Life Sciences reports Q4 net loss $12.4M; reiterates cytisinicline NDA by end of Q2 2025","bullets":["Cash, cash equivalents and marketable securities $34.4M as of Dec 31, 2024.","Net loss for Q4 2024 was $12.4M; full-year net loss $39.8M (pre-revenue).","NDA submission for smoking cessation cytisinicline expected end of Q2 2025; ORCA-OL enrollment complete.","Appointed Mark Oki as CFO, Dr. Kristen Slaoui and Nancy Phelan to Board.","FDA agreed Phase 3 ORCA-V2 trial design for vaping cessation; plans to initiate in H1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-036830","json":"https://secwatch.observer/filing/0000950170-25-036830.json","markdown":"https://secwatch.observer/filing/0000950170-25-036830.md","text":"https://secwatch.observer/filing/0000950170-25-036830.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/949858/000095017025036830/0000950170-25-036830-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/949858/000095017025036830/achv-20250311.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T00:36:52.412556+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}